Heart Rate Variability and Sensorimotor Polyneuropathy in Type 1 Diabetes

STEVEN ORLOV, MD
VERA BRI., MD

ANDREJ ORSZAG, MD
BRUCE A. PERKINS, MD, MPH

OBJECTIVE—Reduced heart rate variability (HRV) is classically viewed as an early phenomenon in diabetic sensorimotor polyneuropathy (DSP). We aimed to determine the characteristics of HRV across the spectrum of clinical DSP in type 1 diabetes.

RESEARCH DESIGN AND METHODS—Eighty-nine diabetic subjects and 60 healthy volunteers underwent assessment of RR interval variation (RRvar) during deep breathing and clinical and electrophysiological examination. We examined the distribution of age-standardized RRvar across the spectrum of clinical DSP, identified variables associated with RRvar in multivariate regression, and compared RRvar with validated measures of neuropathy.

RESULTS—Age-standardized RRvar had a significant, step-wise, inverse relationship with ordinal categories of increasing DSP severity (β = –5.4, P < 0.0001) among subjects with diabetes. Case subjects with DSP had substantially lower age-standardized RRvar compared with diabetic control subjects without DSP (β = –5.2, P < 0.01), although there was substantial overlap of RRvar between diabetic case subjects and control subjects and the healthy volunteer cohort. In multivariate analysis, advanced age was independently associated with lower RRvar in both healthy volunteers and diabetic subjects, whereas higher glycated hemoglobin A1c and systolic blood pressure were independently associated with lower RRvar in diabetic subjects. RRvar had a significant association with validated measures of large and small fiber neuropathy.

CONCLUSIONS—HRV may be a biomarker for clinical DSP and is associated cross-sectionally with both early and late measures of neuropathy. The low HRV observed in some control subjects without DSP and in most case subjects with severe DSP may signify that HRV has different prognostic implications in these groups, requiring further longitudinal study.

Diabetes Care 35:809–816, 2012

Decreased heart rate variability (HRV)—the instantaneous beat-to-beat variation in heart rate during respiration—has long been identified as an early marker of autonomic neuropathy in diabetes, often preceding any other manifestation of neuropathy (1). Since these first observations, the classic dogma has been that decreased HRV is an early, asymptomatic finding in diabetic polyneuropathy (2). In normal individuals, heart rate varies significantly throughout the respiratory cycle—increasing with inspiration and decreasing with expiration—in a phenomenon known as sinus arrhythmia (3). These physiologic changes are mediated by sympathetic and parasympathetic nerves in the autonomic nervous system.

Pathophysiologically, decreased HRV is thought to reflect impaired parasympathetic innervation of the vagus nerve, the longest autonomic nerve, in a length-dependent fashion akin to injury of peripheral somatic nerves in diabetic sensorimotor polyneuropathy (DSP) (4).

HRV during deep breathing is one of several cardiovascular autonomic reflex tests (CARTs) that are part of the gold standard diagnostic criteria for cardiac autonomic neuropathy (CAN) (5), a clinical condition characterized by dysfunction of the autonomic innervation of the cardiovascular system (6). Although the isolated finding of decreased HRV is considered sufficient criterion for possible or early CAN, a second abnormal CART is required for a definite or confirmed diagnosis (5). HRV can be assessed by a variety of metrics, categorized into “time” and “frequency” domains, but HRV with deep breathing in the time domain remains the most commonly used CART and has the greatest specificity for CAN (4).

Recently, several large prospective studies have demonstrated that CAN, defined by HRV criteria, is an independent predictor of cardiovascular disease (CVD) (7,8) and mortality in diabetes (9–12). Intervention trials have shown that intensive glycemic control and a strategy aimed at lifestyle change with pharmacological correction of hyperglycemia, hypertension, dyslipidemia, and microalbuminuria decrease the incidence and progression of CAN (13–15).

To date, several studies have explored the relationship between HRV and microvascular complications of diabetes (16,17). Decreased HRV has been associated with new onset renal impairment (16) as well as cardiovascular mortality in patients with diabetic nephropathy (17). However, the nature of the relationship between HRV and DSP has not been well established (18).

In light of this question and the early diagnostic value of HRV in autonomic neuropathy, we aimed to cross-sectionally evaluate HRV among type 1 diabetic participants in the Toronto Diabetic Early Neuropathy Cohort (19) to determine whether it can serve as a biomarker for DSP based on the gold-standard definition (20). To further elucidate the temporal and pathophysiological relationship underlying decreased HRV, we compared it with validated measures of peripheral neuropathy including functional large fiber sensory and motor measures, as well as functional and morphological small fiber measures.

RESEARCH DESIGN AND METHODS

Subject selection and evaluation

Eighty-nine subjects with type 1 diabetes were accrued from the Endocrinology and Neurology Clinics at the Toronto General Hospital/University Health Network. An additional 60 healthy volunteers were recruited by community advertisement and sampling among family and friends of diabetic subjects. Volunteers were selected to ensure that the distribution of age (by...
decade of life) and sex among healthy volunteers was the same as type 1 diabetic subjects. Together, this cohort continues to be longitudinally followed in a study funded by the Juvenile Diabetes Research Foundation (operating grant no.17-2008-715) examining the concurrent and predictive validity of various measures of neuropathy. Predictive validity, the ability of a baseline test to predict the future onset of neuropathy in subjects without neuropathy at baseline, is actively being pursued in the longitudinal follow-up of this cohort.

A stratified accrual strategy according to the Toronto Clinical Neuropathy Score (TCNS) (21) was used to create a cohort of type 1 diabetic subjects that represented the spectrum of nerve injury, from lack of detectable nerve injury to severe DSP. The TCNS is a 19-point validated clinical neuropathy score in which cumulative scores of 0–5, 6–8, 9–12, and 13–19 represent absent, mild, moderate, and severe neuropathy, respectively (21). Subjects were selected to ensure representation from each of the four TCNS stages at the time of study accrual. All subjects had a diagnosis of type 1 diabetes, were at least 18 years of age, provided informed consent, and did not have neuropathy attributable to causes other than diabetes on the basis of detailed medical history, family history, history of toxin exposure, renal failure, or presence of abnormal serum or urine protein electrophoresis. A comprehensive medical and neurologic evaluation of each participant involved assessment of neuropathy-related symptoms, signs (blood pressure and heart rate), lifestyle factors and comorbidities (including smoking), and biochemical tests (glycated hemoglobin $A_1C$, [HbA1C], serum lipids, and urinary albumin excretion).

The current report evaluates the baseline cross-sectional data from examinations conducted between November 2008 and May 2010. Approval of the protocol and consent procedures was obtained from the Research Ethics Board of the University Health Network.

**Assessment of HRV**
All participants underwent assessment of HRV using the Dantec Keypoint Workstation (Natus Medical, San Carlos, CA). Participants avoided caffeinated beverages, smoking, alcohol, and large meals for at least 2 h before the assessment. The absence of hypoglycemia or marked hyperglycemia was confirmed with capillary blood glucose measurements. A minimum of 30 min in the supine position preceded all electrocardiogram recordings. Two surface electrodes were placed on the chest to obtain an electrocardiogram tracing. A baseline 1-min recording was obtained during normal breathing in a quiet room. The subsequent recording was obtained over 1 min during deep breathing at a frequency of 6 breaths per min (5 s in and 5 s out), with time cues provided by the technician. The built-in software algorithm (22) generated a plot of RR intervals versus time. Positive and negative peaks (maximum and minimum RR intervals) during each respiratory cycle were identified using the three-point search algorithm (22). Peaks with amplitudes greater than 75% above or below the median RR interval were excluded to minimize the effect of ectopic beats and irregular breathing. HRV was expressed as the RR interval variation (RRvar), the difference between the shortest and the longest RR intervals during 1 min given as a percentage of the mean of all peaks $[\text{RRmax} - \text{RRmin}] / \text{RRmean} \times 100\%$. This mathematical algorithm for RRvar was selected among several other formulas because of its small scatter, small number of outliers, and superior correlation with existing nerve conduction parameters during repeated testing in healthy volunteers and those with diabetes (22). The interobserver variability on repeat testing of five subjects was 30%, corresponding to an estimated coefficient of variation of 12% in RRvar with deep breathing units (22).

**Classification of DSP case and control subjects**
The case definition for DSP was consistent with the clinical and electrophysiological criteria set forth by the American Association of Neurology, the American Academy of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation (20). Clinical criteria required the presence of more than one symptom (numbness, tingling, weakness, foot pain, or ataxia) or sign (abnormal knee or ankle reflexes, temperature, light touch, monofilament, or vibration sensation), in keeping with a distal symmetrical neuropathic pattern of onset and progression. Electrophysiological abnormality was defined by at least one abnormal nerve conduction study (NCS) parameter in both dominant-side sural and peroneal nerve distributions assessed using the Counterpoint instrument (Natus Medical) with age- and height-adjusted thresholds for abnormality (23). Two sural nerve parameters (action potential amplitude and conduction velocity) and three peroneal nerve parameters (distal compound muscle action potential amplitude, F-wave latency from ankle stimulation, conduction velocity from fibular head stimulation) were tested. Type 1 diabetic control subjects without DSP were divided into two groups based on the presence or absence of sural nerve abnormalities. Mild, moderate, and severe DSP were defined by the first, second, and third tertile of TCNS score, respectively.

**Assessment of small fiber morphology and function**
As described previously (19), corneal nerve fiber length (CNFL) was assessed using corneal confocal microscopy (CCM) with the Rostock Cornea Module of the Heidelberg Tomograph II (Heidelberg Engineering, Smithfield, RI) (24). In brief, the mean CNFL from both eyes was calculated from high contrast images of the subbasal nerve plexus in Bowman’s layer of the cornea using analytical software (CCM Image Analysis tool v0.6 provided by Drs. R. Malik and M. Dabbah; University of Manchester) and expressed in millimeters per squared millimeters of Bowman’s layer.

Cooling detection threshold was obtained using the Medoc TSA-II NeuroSensory Analyzer (Ramat-Yishai, Israel) and the method of limits, as described previously (25). In brief, a stimulator was applied to the dorsum of the right foot at a temperature of 32°C and the temperature was gradually decreased to the first level detected by the patient as being cooler than the preceding stimulus. Five test trials were performed and averaged to establish a mean cooling detection threshold in °C.

As described previously (26), axon-reflex mediated neurogenic vasodilation in response to cutaneous heating by the laser Doppler imaging flare technique (LDIFLARE) was measured using equipment from Moor Instruments (Axminster, U.K.). In brief, a skin-heating probe was applied to the dorsum of the right foot and heated to the skin to 44°C for 20 min. Laser Doppler imaging using the moorLDI2 (Moor Instruments) (26) was used to register movement of erythrocytes in dermal capillaries over a 6 cm × 6 cm area. The LDIFLARE area was calculated in squared centimeter using Moor LDI software (version 3.11).

**Statistical analysis**
Analysis was performed using SAS version 9.0 for Windows. Differences in categorical variables between healthy volunteers and type 1 diabetic subjects with and without DSP were assessed using the $\chi^2$ test, whereas continuous variables were assessed using ANOVA. Results were expressed as...
mean ± SD. The interquartile range (25th, 75th percentile), 90% distribution (5th, 95th percentile), and 95% distribution (2.5th, 97.5th percentile) were identified for RRvar and age-standardized RRvar values during normal and deep breathing. Age-standardized RRvar was calculated from a linear regression model for the existing dataset that included RRvar as the dependent variable and age and neuropathy subgroups as independent variables. Dependent predictor variables for the univariate and multivariate linear regression models with RRvar were assessed by standard regression diagnostics. We estimated 99.3% power to detect a significant difference in the diabetes subgroup alone in our cohort of 60 healthy volunteers, 62 diabetic control subjects subgroup alone in our cohort of 60 healthy volunteers, 62 diabetic control subjects without DSP, and 21 diabetic subjects with DSP. This estimate was based on α = 0.05, mean RRvar (40%), and standard deviation (10%) derived from the report of a comparable aged cohort using the same HRV measurement method (22), and assuming an anticipated 20% difference between diabetic subjects with and without DSP.

RESULTS—The clinical characteristics of the 149 study participants are summarized in Table 1. The cohort consisted of 60 healthy volunteers and 89 subjects with type 1 diabetes (62 control subjects without DSP and 27 case subjects with DSP). Individuals with type 1 diabetes and DSP were significantly older and had longer diabetes duration and higher systolic blood pressures. Subjects with type 1 diabetes had higher BMI, systolic blood pressure, and HbA1c, but lower LDL cholesterol and higher HDL cholesterol levels, compared with healthy volunteers. The TCNS, a clinical indicator of nerve injury severity, was higher among type 1 diabetic subjects than healthy volunteers. Generally, NCS parameters were most abnormal among type 1 diabetic case subjects with DSP compared with control subjects without DSP and healthy volunteers. Both RRvar during normal and deep breathing were generally lower in those with diabetes compared with healthy volunteers, but diabetic control subjects without DSP had the highest mean values. This was accounted for by the younger age distribution in this subgroup. To adjust for this effect we present age-standardized values. The age-standardized RRvar was significantly lower in type 1 diabetic case subjects with DSP, compared with both type 1 diabetic control subjects without DSP and healthy volunteers during both normal (P < 0.0001) and deep (P < 0.0001) breathing. The difference in age-standardized RRvar between healthy volunteers and type 1 diabetic control subjects without DSP was significant during normal (t-statistic = 2.00, P < 0.05), but not during deep (t-statistic = 1.43, P = 0.16), breathing.

To explore the relationship of age-standardized RRvar during deep breathing among healthy volunteers and subjects with type 1 diabetes, we examined its distribution across a broad spectrum of nerve injury (Fig. 1). Subjects with type 1 diabetes had a significantly lower age-standardized RRvar during deep breathing than healthy volunteers (t-statistic = 4.85, P < 0.0001). As shown in Fig. 1, second to sixth

### Table 1—Clinical characteristics of the 60 healthy volunteers and the 89 type 1 diabetic participants according to DSP status

| Clinical characteristic                      | Healthy volunteers (n = 60) | Control subjects without DSP (n = 62) | Case subjects with DSP (n = 27) | ANOVA P value for trend* |
|---------------------------------------------|----------------------------|--------------------------------------|--------------------------------|-------------------------|
| Female sex, n (%)                           | 28 (47)                   | 33 (53)                              | 17 (63)                        | 0.36                    |
| Age (years)                                 | 37.9 ± 16.9               | 33.5 ± 13.7                          | 48.2 ± 13.3                    | 0.0002                  |
| Diabetes duration (years)                   | -                         | 18.1 ± 13.3                          | 32.0 ± 12.5                    | <0.0001                 |
| Current/recent smoking, n (%)               | 13 (22)                   | 9 (15)                               | 5 (19)                         | 0.59                    |
| Height (m)                                  | 1.7 ± 0.1                 | 1.7 ± 0.1                            | 1.7 ± 0.1                      | 0.43                    |
| Weight (kg)                                 | 73.1 ± 17.3               | 76.1 ± 14.5                          | 83.7 ± 23.2                    | 0.08                    |
| BMI (kg/m²)                                 | 24.9 ± 5.1                | 25.3 ± 4.2                           | 28.4 ± 5.9                     | 0.03                    |
| Blood pressure (mmHg)                       |                           |                                      |                                |                         |
| Systolic                                    | 124 ± 14                  | 123 ± 14                             | 136 ± 16                       | 0.0003                  |
| Diastolic                                    | 75 ± 10                   | 70 ± 8                               | 75 ± 10                        | 0.01                    |
| Heart rate at rest (bpm)                    | 68 ± 11                   | 68 ± 13                              | 72 ± 13                        | 0.34                    |
| HbA1c (%)                                   | 5.6 ± 0.4                 | 7.5 ± 12                             | 8.4 ± 1.6                      | <0.0001                 |
| Cholesterol (mmol/L)                        |                           |                                      |                                |                         |
| Total                                        | 4.6 ± 1.0                 | 4.5 ± 0.8                            | 4.4 ± 1.0                      | 0.65                    |
| LDL                                          | 2.7 ± 0.8                 | 2.4 ± 0.7                            | 2.3 ± 0.7                      | 0.03                    |
| HDL                                          | 1.4 ± 0.4                 | 1.7 ± 0.4                            | 1.7 ± 0.5                      | 0.02                    |
| Triglycerides (mmol/L)                      | 1.0 ± 0.5                 | 0.9 ± 0.6                            | 1.1 ± 0.8                      | 0.28                    |
| TCNS, median [IQR]‡                          | 0 [0, 2]                  | 2 [1, 5]                             | 8 [5, 12]                      | <0.0001                 |
| Sural nerve amplitude potential (μV)        | 18 ± 9                    | 11 ± 5                               | 3 ± 2                          | <0.0001                 |
| Sural nerve conduction velocity (m/s)       | 51 ± 5                    | 46 ± 4                               | 40 ± 3                         | <0.0001                 |
| Peroneal nerve amplitude potential (μV)     | 6 ± 2                     | 6 ± 2                                | 2 ± 1                          | <0.0001                 |
| Peroneal nerve conduction velocity (m/s)    | 48 ± 3                    | 43 ± 3                               | 37 ± 5                         | <0.0001                 |
| RRvar with normal breathing (%)             |                           |                                      |                                |                         |
| Mean ± SD                                   | 23 ± 16                   | 27 ± 16                              | 12 ± 11                        | 0.0003                  |
| Age-standardized mean ± SD                  | 25 ± 5                    | 23 ± 4                               | 16 ± 4                         | <0.0001                 |
| IQR                                          | 12, 29                    | 15, 36                               | 6, 14                          |                         |
| 90% Distribution                            | 15, 69                    | 6, 60                                | 3, 36                          |                         |
| 95% Distribution                            | 13, 72                    | 6, 66                                | 2, 43                          |                         |
| RRvar with deep breathing (%)               |                           |                                      |                                |                         |
| Mean ± SD                                   | 37 ± 20                   | 44 ± 23                              | 21 ± 16                        | <0.0001                 |
| Age-standardized mean ± SD                  | 40 ± 8                    | 38 ± 6                               | 27 ± 6                         | <0.0001                 |
| IQR                                          | 20, 48                    | 26, 52                               | 10, 26                         |                         |
| 90% Distribution                            | 15, 79                    | 12, 100                              | 4, 45                          |                         |
| 95% Distribution                            | 13, 96                    | 11, 113                              | 3, 74                          |                         |

Data are means ± SD unless otherwise indicated. [IQR] represents the interquartile range. bpm, beats per minute. *P values for categorical variables were calculated with the χ² test, and ANOVA was used for continuous variables. ‡Scores of 0–5 are considered to represent low likelihood of DSP, 6–8 represent likelihood of mild neuropathy, 9–12 represent likelihood of moderate neuropathy, and 13–19 represent likelihood of severe neuropathy.
box-and-whisker plots, among subjects with diabetes, age-standardized $RR_{\text{var}}$ with deep breathing had a significant, step-wise, inverse relationship with ordinal categories of increasing DSP severity, from type 1 diabetic control subjects without and with evidence of subclinical sural nerve injury to DSP case subjects divided into mild, moderate, and severe according to TCNS tertile (linear regression $b = -5.4$, $P < 0.0001$). In comparison with healthy volunteers, type 1 diabetic control subjects without DSP and without subclinical sural nerve injury had no significant difference in age-standardized $RR_{\text{var}}$ with deep breathing (linear regression $b = 0.09$, $P = 0.08$) (Fig. 1, first and second box-and-whisker plots). Age-standardized $RR_{\text{var}}$ with deep breathing was significantly lower among type 1 diabetic control subjects with subclinical sural nerve injury compared with control subjects without subclinical sural nerve injury (linear regression $b = -8.3$, $P < 0.0001$) (Fig. 1, second and third box-and-whisker plots). Case subjects with DSP had substantially lower age-standardized $RR_{\text{var}}$ with deep breathing compared with diabetic control subjects without DSP (linear regression $b = -5.15$, $P < 0.01$). Among case subjects with DSP, age-standardized $RR_{\text{var}}$ with deep breathing had an inverse relationship with increasing neuropathy severity (linear regression $b = -6.8$, $P = 0.05$) (Fig. 1, fourth to sixth box-and-whisker plots).

We performed a univariate and multivariate regression analysis of $RR_{\text{var}}$ with deep breathing using the baseline variables from Table 1 and present it in Table 2. Among subjects with type 1 diabetes, $RR_{\text{var}}$ with deep breathing was lower in univariate linear regression analysis with advanced age, higher systolic and diastolic blood pressures, higher TCNS score, and more abnormal values of large fiber NCS measures. The same association with age, TCNS score, and peroneal nerve conduction velocity was seen among healthy volunteers. In multivariate analysis, the only variable independently associated with lower $RR_{\text{var}}$ with deep breathing in both healthy volunteers and type 1 diabetic subjects was advanced age. However, higher systolic blood pressure and higher HbA1c were additionally independently associated with lower $RR_{\text{var}}$ in type 1 diabetic subjects.

With respect to measures of small fiber neuropathy in the subjects with type 1 diabetes, univariate regression analysis demonstrated that lower $RR_{\text{var}}$ with deep breathing was associated with shorter CNFL and lower cooling detection threshold, but no association with LDIFLARE area was observed. These associations are shown graphically by way of scatterplots to compare $RR_{\text{var}}$ with validated measures of large and small fiber neuropathy in subjects with type 1 diabetes (Fig. 2). Lower $RR_{\text{var}}$ with deep breathing was associated with slower peroneal and sural nerve conduction velocities (linear regression $b = 2.22$, $P < 0.0001$; $b = 1.69$, $P = 0.0008$) (Fig. 2, scatterplots A and B). Lower $RR_{\text{var}}$ with deep breathing was also associated with shorter CNFL (linear regression $b = 1.84$, $P = 0.0002$) and lower cooling detection threshold (linear regression $b = 1.51$, $P < 0.0001$), but not smaller LDIFLARE area (linear regression $b = 3.24$, $P = 0.13$) (Fig. 2, scatterplots C–E). All associations between $RR_{\text{var}}$ with deep breathing and measures of small and large fiber neuropathy were not independent of the relationship of age with each type of neuropathy measure (data not shown).

**CONCLUSIONS**—In evaluating a cohort of type 1 diabetic subjects representing the spectrum of neuropathy, we found a strong incremental association between lower HRV, as measured by $RR_{\text{var}}$ with deep breathing, and increasing degrees of DSP severity. Despite this association with
late-stage clinical DSP, we observed a wide range of HRV, including low HRV, among our healthy volunteer cohort who had the same sex and age distribution as type 1 diabetic subjects. This observation prompted us to search for independent predictors of HRV that may preexist in healthy individuals. Our regression analysis highlights the independent association between lower HRV and advanced age in both healthy volunteers and subjects with diabetes, as well as the inverse association of HRV with blood pressure and glyemic exposure in diabetic subjects. HRV was found to have a significant positive association with validated measures of small and large fiber nerve function, suggesting that it may perform as a marker of DSP in both early and late stages of neuropathy.

Decreased HRV has classically been identified as the earliest manifestation of autonomic neuropathy (1), which may mark the first committed step toward neuropathic diabetes outcomes such as clinical DSP (2). However, it has been well-established that HRV has prognostic utility in predicting nonneuropathic diabetes outcomes such as CVD (7,8) and mortality (9–12). There exist many putative intermediaries on the causal pathway between low HRV and mortality. Although preliminary as a result of the cross-sectional nature of the current study, our results suggest that DSP may play a role in the causal relationship between low HRV and mortality. The current study shows a clear association between lower HRV and increasing degrees of DSP severity, which are in agreement with existing literature (18). Although previous studies have identified DSP to be an independent predictor for developing abnormal/low HRV prospectively (31), no study has examined whether the opposite relationship—low HRV independently predicting future DSP onset—is also true. The current study also revealed a subset of individuals without evidence of DSP that have HRV as low as those with severe DSP and thus raises a fundamental question about the implications of CAN as an independent predictor of nonneuropathic outcomes in diabetes. Specifically, does the low HRV that we observed in diabetic subjects with absent or mild DSP carry the same prognostic importance for CVD and mortality as the low HRV that is present in case subjects with severe DSP? Prospective follow-up of the current cohort and other validation studies will be required to establish whether HRV is an independent predictor of DSP onset and whether HRV can predict CVD and mortality independent of DSP as an intermediary.

Several studies have examined the clinical correlates and predictors of HRV, typically when abnormally low levels of HRV itself were used as the diagnostic criteria for CAN (32–36). Similar to our findings, a progressive reduction in HRV is seen with increasing age among normal subjects (33) and in patients with diabetes (34–36). These relationships have led to the recommendation of age-specific normal threshold values for a variety of CARTs, including HRV with deep breathing (5). Our results also agree with the independent association of glyemic exposure and lower HRV as assessed by HbA1c (34,35). The inverse

Table 2—Association of baseline demographics with RRvar with deep breathing

| Baseline clinical characteristics | Healthy volunteers (n = 60) | Type 1 diabetes (n = 89) |
|---------------------------------|---------------------------|------------------------|
|                                 | β  | P       | β            | P         |
| Female sex                      | −1.68 | 0.75 | −0.009 | 0.99 |
| Age (years)                     | −0.39 | 0.01 | −0.59 | 0.0002 |
| Diabetes duration (years)       | —  | —     | −0.50 | 0.16 |
| Current/recent smoking          | 3.88 | 0.55 | −0.90 | 0.90 |
| Height (m)                      | 5.60 | 0.86 | 19.19 | 0.50 |
| Weight (kg)                     | 0.11 | 0.51 | −0.12 | 0.47 |
| BMI (kg/m²)                     | 0.40 | 0.48 | −0.87 | 0.15 |
| Blood pressure (mmHg)           | −0.36 | 0.06 | −0.52 | <0.0001 |
| Systolic                        | −0.23 | 0.38 | −0.20 | 0.008 |
| Heart rate at rest (bpm)        | −0.39 | 0.12 | −0.32 | 0.09 |
| HbA1c (%)                       | −8.88 | 0.24 | −3.80 | 0.06 |
| Cholesterol (mmol/L)            | Total | 0.38 | 2.60 | 0.48 |
| LDL                             | 2.85 | 0.46 | 1.47 | 0.75 |
| HDL                             | 2.26 | 0.26 | 5.12 | 0.48 |
| Triglycerides (mmol/L)          | −4.83 | 0.41 | −7.86 | 0.09 |
| Large fiber neuropathy measures | TCNS | −3.55 | 0.005 | −1.87 | 0.0008 |
| Sural nerve amplitude potential (µV) | 0.30 | 0.32 | 1.30 | 0.002 |
| Sural nerve conduction velocity (m/s) | 1.08 | 0.06 | 1.69 | 0.0008 |
| Peroneal nerve amplitude potential (µV) | 0.96 | 0.41 | 3.09 | 0.0009 |
| Peroneal nerve conduction velocity (m/s) | 1.91 | 0.009 | 2.22 | <0.0001 |
| Small fiber neuropathy measures | CNFL (mm/mm²) | 0.79 | 0.20 | 1.84 | 0.0002 |
| LDIFLARE area (cm²)‡             | 1.67 | 0.27 | 3.24 | 0.13 |
| Cooling detection threshold (°C) | 0.55 | 0.40 | 1.51 | <0.0001 |
| Multivariate analysis‡          | Age (years) | −0.34 | 0.04 | −0.51 | 0.003 |
| Systolic blood pressure (mmHg)  | −0.25 | 0.22 | −0.36 | 0.03 |
| HbA1c (%)–forced                | −1.22 | 0.89 | −4.40 | 0.02 |

Data represent linear regression slope (β) and P value for the relationship between RRvar (the dependent variable) and the independent variables listed in the first column. bpm, beats per minute; ‡Axon-reflex mediated neurogenic vasodilatation by the laser Doppler imaging method. The multivariate model included the variables that were significant in univariate analysis in either the healthy volunteer or type 1 diabetes cohorts. Direct measures of neuropathy, which included the TCNS, nerve conduction studies, and small fiber measures, were not considered in the multivariate analysis.
relationship between blood pressure and HRV in subjects with diabetes has also been reported in the literature (32–36), although, contrary with the results from our cohort, others have observed this relationship in healthy volunteers (33). Our findings are in close agreement with a study by Valensi et al. (36), who found that age, diabetes duration, and blood pressure were independent predictors of HRV with deep breathing among subjects with type 1 diabetes. Although we could not confirm a relationship between higher BMI and lower HRV, others have demonstrated such association in type 2 diabetes (36) and in unselected populations (37). Unlike previous reports (34), our study found no significant correlation between HRV and fasting

**Figure 2**—Association of RRvar with deep breathing and validated measures of large fiber (A and B) and small fiber (C–E) neuropathy. Scatterplots of RRvar with deep breathing and measures of large fiber motor function (peroneal nerve conduction velocity, A); large fiber sensory function (sural nerve conduction velocity, B); small fiber morphology (corneal nerve fiber length, C); and small fiber function (cooling detection threshold, D; LDIFLARE area, E), among subjects with type 1 diabetes are shown.
triglyceride levels or cigarette smoking. Taken together, our observations highlight the notion that decreased HRV is an age-dependent phenomenon that may often predate the onset of diabetes, although poor glycemic control is independently associated with lower values among those with diabetes. The significant inverse relationship between blood pressure and HRV may be the result of increased sympathetic tone after the parasympathetic denervation putatively associated with CAN, although the temporal relationship between these variables will require prospective study. In view of the independent association of HRV with age, present even in healthy volunteers at low risk for the development of polyneuropathy, any protocol that considers the use of HRV to identify the presence of DSP or to predict its future onset will need to incorporate age-stratified diagnostic thresholds.

HRV is primarily mediated by efferent parasympathetic B and C small nerve fiber function (38). Other measures of small fiber function include quantitative sensory tests (i.e., cooling detection threshold) (25), which assess afferent C and Aδ fibers, as well as axon reflex-mediated neurogenic vasodilatation in response to nociceptive stimuli (i.e., LDIFLARE) (26), which assess afferent C fiber function. Small fibers can also be assessed morphologically using CCM to measure CNFL (19,24). In contrast, abnormalities on NCS that define the presence of DSP reflect loss of large nerve fiber function comprising myelinated Aα and Aβ fibers. Although confounded by age, the current study found a significant positive association between HRV and measures of large fiber motor and sensory function, as well as small fiber sensory function (cooling detection threshold). We also report the novel finding that lower HRV is associated with shorter CNFL. Similar to our findings, a previous study among 43 subjects with DSP found that those with CAN, defined by HRV criteria, were more likely to have abnormalities in thermal perception thresholds, sympathetic skin response, and quantitative sudomotor axon reflex tests (39). The results of the current study suggest that HRV, as a measure of small fiber neuropathy, is associated with measures of both small and large fiber neuropathy and hence is present in both early and late phenotypes of diabetic neuropathy.

Although unique as a study to evaluate the relationship of HRV and DSP, there are several limitations to the results of this study. First, we acknowledge that the measurement of HRV using RRvar, with deep breathing as developed by Stålberg and Nogués (22) is not the only, nor most commonly operationalized, method for assessing HRV. Despite its benefits of being automated and easily integrated with concurrent NCS and algorithmic attempts to minimize the effect of ectopic beats, alternative methods such as calculation of the mean circular resultant using vector analysis (40) have been shown to further attenuate the effect of trends in heart rate over time and the effect of basal heart rate (4). Second, the relevance of this data to type 2 diabetes requires further study. Third, we acknowledge that the most important clinical outcome for establishing HRV as a biomarker will be the future onset of DSP through longitudinal follow-up. The current cross-sectional study is the first step toward this objective, although large prospective study will be required to fully elucidate the predictive validity of HRV for DSP. Fourth, although we identify the major variables that are independently associated with HRV, we likely have insufficient power to detect variables with minor but reportedly significant associations such as smoking or serum triglyceride levels. Finally, we were unable to confidently identify abnormal threshold values for RRvar with deep breathing, as calculated by Stålberg and Nogués (22), that could determine risk for concurrent DSP and thus elected to study its relationship as a continuous variable.

In summary, HRV may be a biomarker for clinical DSP and is associated cross-sectionally with both early and late measures of neuropathy. The current study establishes the need to prospectively examine the role of HRV in predicting DSP onset and suggests that DSP may play a role in the causal relationship between HRV and CVD and mortality.

Acknowledgments—This research was supported by the Juvenile Diabetes Research Foundation Grant 17-2007-715. B.A.P. was a Canadian Diabetes Association Scholar. S.O. was supported by a Residency Research Elective from the University of Toronto Internal Medicine Program.

No potential conflicts of interest relevant to this article were reported.

S.O. and B.A.P. researched the data and performed the statistical analysis of the data. S.O. prepared the first draft of the manuscript. V.B., A.O., and B.A.P. reviewed the manuscript for scholarly content and accuracy. V.B. and B.A.P. created the study hypothesis and objective and designed the study. B.A.P. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Murray A, Ewing DJ, Campbell IW, Neilson JM, Clarke BF. RR interval variations in young male diabetics. Br Heart J 1975;37: 882–885
2. Dyck JB, Dyck PJ. Diabetic polyneuropathy. In Diabetic Neuropathy. Dyck PJ, Thomas PK, Eds. Philadelphia, W.B. Saunders, 1999, p. 255–278
3. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med 1980;49:95–108
4. Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 2010;33:434–441
5. Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. In press
6. Tesfaye S, Boulton AJ, Dyck PJ, et al.; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33:2285–2293
7. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26:1553–1570
8. Young LH, Wackers FJ, Chyun DA, et al.; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009;301:1547–1555
9. Pop-Busui R, Evans GW, Gerstein HC, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010;33:1578–1584
10. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003;26:1895–1901
11. Ziegler D, Zentai CP, Perz S, et al.; KORA Study Group. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008;31: 556–561
12. Wheeler SG, Ahroni JH, Boyko EJ. Propective study of autonomic neuropathy as a predictor of mortality in patients with diabetes. Diabetes Res Clin Pract 2002; 58:131–138
13. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Program.
HRV and diabetic polyneuropathy

Trial (DCCT). Diabetologia 1998;41:416–423
14. Pop-Busui R, Low PA, Waberski BH, et al.; DCCT/EDIC Research Group. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009;119:2886–2893
15. Gaede P, Vedel P, Parving HH, Pedersen O. Intensiﬁed multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617–622
16. Brotman DJ, Bash LD, Qayyum R, et al. Heart rate variability predicts ESRD and CKD-related hospitalization. J Am Soc Nephrol 2010;21:1560–1570
17. Chandra P, Sands RL, Gillespie BW, et al. Predictors of heart rate variability and its prognostic signiﬁcance in chronic kidney disease. Nephrol Dial Transplant. In press
18. Ziegler D, Pedersen O. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy. Diabet Med 1992;9:806–814
19. Hertz P, Bril V, Orszag A, et al. Reproducibility of in vivo corneal confocal microscopy as a novel screening test for early diabetic sensorimotor polyneuropathy. Diabet Med 2011;28:1209–1214
20. England JD, Gronseth GS, Franklin G, et al.; American Academy of Neurology; American Association of Electrodagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Distal symmetric polyneuropathy: a deﬁnition for clinical research: report of the American Academy of Neurology, the American Association of Electrodagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2003;64:199–207
21. Perkins BA, Oalayye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001;24:250–256
22. Stålberg EV, Nogués MA. Automatic analysis of heart rate variation: I. Method and reference values in healthy controls. Muscle Nerve 1989;12:993–1000
23. Oh SJ. Normal values for common nerve conduction tests. In Clinical Electromyography: Nerve Conduction Studies. 3rd ed. Philadelphia, Lipincott Williams & Wilkins, 2003, p. 86–106
24. Tavakoli M, Malik RA. Corneal confocal microscopy: a novel non-invasive technique to quantify small ﬁbre pathology in peripheral neuropathies. J Vis Exp. In press
25. Zinman LH, Bril V, Perkins BA. Cooling detection thresholds in the assessment of diabetic sensory polyneuropathy: comparison of CASE IV and Medoc instruments. Diabetes Care 2004;27:1674–1679
26. Krishnan ST, Rayman G. The LDI® standardization of heart rate variability, Criterion by Benchmark, LDI, Inc. 2004;27:175–181
27. Cardoso CR, Leite NC, Freitas L, Dias SB, Muxfeld ES, Salles GF. Pattern of 24-hour ambulatory blood pressure monitoring in type 2 diabetic patients with cardiovascular dysautonomy. Hypertens Res 2008;31:865–872
28. Veglio M, Chinaglia A, Cavallo-Perin P. QT interval, cardiovascular risk factors and risk of death in diabetes. J Endocrinol Invest 2004;27:175–181
29. Lykke JA, Tarnow L, Parving HH, Hilsted J. Reduction of autonomic function in peripheral neuropathy: the Steno type 2 randomised study (DCCT/EDIC). Circulation 2009;119:2886–2893
30. Lykke JA, Tarnow L, Parving HH, Hilsted J. A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes. Scand J Clin Lab Invest 2008;68:654–659
31. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007;115:387–397
32. Perkins BA, Oalayye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001;24:250–256
33. Ayad F, Bellajd M, Pariés J, Attali JR, Valensi P. Association between cardiac autonomic neuropathy and hypertension and its potential inﬂuence on diabetic complications. Diabet Med 2010;27:804–811
34. Selber DA, Pfeifer M, Dawson B, Schuemer M. Cardiovascular autonomic nervous system tests: determination of normative values and effect of confounding variables. J Auton Nerv Syst 1997;62:40–44
35. Kempler P, Tesfaye S, Chaturvedi N, et al.; EURODIAB IDDM Complications Study Group. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med 2002;19:900–909
36. Valensi P, Pariés J, Attali JR; French Group for Research and Study of Diabetic Neuropathy. Cardiovascular autonomic neuropathy in diabetic patients: inﬂuence of diabetes duration, obesity, and microangiopathic complications—the French multicenter study. Metabolism 2003;52:815–820
37. Valensi P, Extramiana F, Lange C, et al.; DESIR Study Group. Inﬂuence of blood glucose on heart rate and cardiovascular function. The DESIR study. Diabet Med 2011;28:440–449
38. Shahani BT, Day TJ, Cros D, Khalil N, Kneebone CS. RR interval variation and the sympathetic skin response in the assessment of autonomic function in peripheral neuropathy. Arch Neurol 1990;47:659–664
39. Spitzer A, Lang E, Birklein F, Klaus D, Neundorfer B. Cardiac autonomic involvement and peripheral nerve function in patients with diabetic neuropathy. Funct Neurol 1997;12:115–122
40. Weinberg CR, Pfeifer MA. An improved method for measuring heart-rate variability: assessment of cardiac autonomic function. Biometrics 1984;40:855–861